| http://dbpedia.org/ontology/abstract
|
Immutep Ltd (formerly Prima Biomed) is a b … Immutep Ltd (formerly Prima Biomed) is a biotechnology company working primarily in the field of cancer immunotherapy using the LAG3 immune control mechanism. The company was originally built on CVac, a therapeutic cancer vaccine. In late 2014 the privately held French immunotherapy company Immutep SA was purchased by Prima Biotech. Prima currently has three main products in its pipeline, all acquired with Immutep: Eftilagimod alpha, (lab name: IMP321) which is recombinant soluble LAG-3, used as an activator of antigen presenting cells. This product has completed a Phase IIa clinical study, where it doubled the expected response rate in HER2-negative metastatic breast cancer. IMP731, a depleting monoclonal antibody for autoimmune diseases, targeting LAG-3+ activated T cells. This antibody has been licensed to GlaxoSmithKline. IMP701, an antagonist monoclonal antibody to LAG3 for use in cancer. This product has been licensed to NovartisThis product has been licensed to Novartis
|
| http://dbpedia.org/ontology/foundingYear
|
2001
|
| http://dbpedia.org/ontology/industry
|
http://dbpedia.org/resource/Biotechnology +
|
| http://dbpedia.org/ontology/keyPerson
|
http://dbpedia.org/resource/Marc_Voigt +
, http://dbpedia.org/resource/CEO +
, http://dbpedia.org/resource/Fr%C3%A9d%C3%A9ric_Triebel +
|
| http://dbpedia.org/ontology/location
|
http://dbpedia.org/resource/Sydney +
, http://dbpedia.org/resource/Germany +
, http://dbpedia.org/resource/Leipzig +
, http://dbpedia.org/resource/Australia +
|
| http://dbpedia.org/ontology/product
|
http://dbpedia.org/resource/GSK2831781 +
, http://dbpedia.org/resource/CVac +
, http://dbpedia.org/resource/IMP321 +
|
| http://dbpedia.org/ontology/thumbnail
|
http://commons.wikimedia.org/wiki/Special:FilePath/Logo-immutep-lag-3.svg?width=300 +
|
| http://dbpedia.org/ontology/type
|
http://dbpedia.org/resource/Public_company +
|
| http://dbpedia.org/ontology/wikiPageExternalLink
|
http://www.immutep.com/ +
, https://www.google.com/search%3Fsa=X&tbm=fin&q=ASX:%2BIMM&stick=H4sIAAAAAAAAAONgecRowS3w8sc9YSn9SWtOXmPU5OIKzsgvd80rySypFJLmYoOyBKX4uXj10_UNDZPNCovzKjPKeQDQyRoZPQAAAA&ved=0ahUKEwjEs_XEo_naAhVDzbwKHc5iBOIQlq4CCDIwAA&biw=1536&bih=734%23scso=uid_XUDzWueZJ8ew8wXLlYjQAQ_5:0 +
|
| http://dbpedia.org/ontology/wikiPageID
|
46505228
|
| http://dbpedia.org/ontology/wikiPageLength
|
15361
|
| http://dbpedia.org/ontology/wikiPageRevisionID
|
1085167624
|
| http://dbpedia.org/ontology/wikiPageWikiLink
|
http://dbpedia.org/resource/Martin_Rogers +
, http://dbpedia.org/resource/Novartis +
, http://dbpedia.org/resource/Immunoglobulin +
, http://dbpedia.org/resource/Merck_Serono +
, http://dbpedia.org/resource/Orsay +
, http://dbpedia.org/resource/CVac +
, http://dbpedia.org/resource/Public_company +
, http://dbpedia.org/resource/Institut_Gustave_Roussy +
, http://dbpedia.org/resource/Dendritic_cells +
, http://dbpedia.org/resource/Tuberculin +
, http://dbpedia.org/resource/Category:Pharmaceutical_companies_of_Australia +
, http://dbpedia.org/resource/Psoriasis +
, http://dbpedia.org/resource/Checkpoint_inhibitor +
, http://dbpedia.org/resource/CEO +
, http://dbpedia.org/resource/Immunotherapy +
, http://dbpedia.org/resource/Progression-free_survival +
, http://dbpedia.org/resource/Pembrolizumab +
, http://dbpedia.org/resource/Paris +
, http://dbpedia.org/resource/Ovarian_cancer +
, http://dbpedia.org/resource/Fr%C3%A9d%C3%A9ric_Triebel +
, http://dbpedia.org/resource/IMP321 +
, http://dbpedia.org/resource/GSK2831781 +
, http://dbpedia.org/resource/Russell_J._Howard +
, http://dbpedia.org/resource/Macquarie_Street%2C_Sydney +
, http://dbpedia.org/resource/American_depositary_receipt +
, http://dbpedia.org/resource/Type_IV_hypersensitivity +
, http://dbpedia.org/resource/Chemoimmunotherapy +
, http://dbpedia.org/resource/Leipzig +
, http://dbpedia.org/resource/Adjuvant +
, http://dbpedia.org/resource/Australia +
, http://dbpedia.org/resource/T_helper_cell +
, http://dbpedia.org/resource/Paclitaxel +
, http://dbpedia.org/resource/Immune_checkpoint +
, http://dbpedia.org/resource/GlaxoSmithKline +
, http://dbpedia.org/resource/Biotechnology +
, http://dbpedia.org/resource/T_cells +
, http://dbpedia.org/resource/P_value +
, http://dbpedia.org/resource/Sydney +
, http://dbpedia.org/resource/Statistical_significance +
, http://dbpedia.org/resource/Drug_pipeline +
, http://dbpedia.org/resource/Nasdaq +
, http://dbpedia.org/resource/Lucy_Turnbull +
, http://dbpedia.org/resource/Monoclonal_antibody +
, http://dbpedia.org/resource/LAG3 +
, http://dbpedia.org/resource/HER2 +
, http://dbpedia.org/resource/Austin_Hospital%2C_Melbourne +
, http://dbpedia.org/resource/Burnet_Institute +
, http://dbpedia.org/resource/Epithelial +
, http://dbpedia.org/resource/Protein_dimer +
, http://dbpedia.org/resource/Marc_Voigt +
, http://dbpedia.org/resource/Wilmersdorf +
, http://dbpedia.org/resource/CoStim +
, http://dbpedia.org/resource/Response_Evaluation_Criteria_in_Solid_Tumors +
, http://dbpedia.org/resource/Ordinary_shares +
, http://dbpedia.org/resource/Berlin +
, http://dbpedia.org/resource/Germany +
, http://dbpedia.org/resource/Reverse_takeover +
, http://dbpedia.org/resource/Cancer_vaccine +
, http://dbpedia.org/resource/Eftilagimod_alpha +
, http://dbpedia.org/resource/Konstanzer_Stra%C3%9Fe_%28Berlin_U-Bahn%29 +
, http://dbpedia.org/resource/Fusion_protein +
, http://dbpedia.org/resource/Australian_Securities_Exchange +
, http://dbpedia.org/resource/Category:Cancer_organisations_based_in_Australia +
|
| http://dbpedia.org/property/foundation
|
2001
|
| http://dbpedia.org/property/industry
|
http://dbpedia.org/resource/Biotechnology +
|
| http://dbpedia.org/property/keyPeople
|
http://dbpedia.org/resource/Fr%C3%A9d%C3%A9ric_Triebel +
, http://dbpedia.org/resource/Marc_Voigt +
|
| http://dbpedia.org/property/location
|
http://dbpedia.org/resource/Leipzig +
, http://dbpedia.org/resource/Australia +
, http://dbpedia.org/resource/Germany +
, http://dbpedia.org/resource/Sydney +
|
| http://dbpedia.org/property/logo
|
Logo-immutep-lag-3.svg
|
| http://dbpedia.org/property/name
|
Immutep Ltd
|
| http://dbpedia.org/property/products
|
IMP321, GSK2831781, CVac LAG-3 Immunotherapy
|
| http://dbpedia.org/property/tradedAs
|
NASDAQ:IMMP
|
| http://dbpedia.org/property/type
|
http://dbpedia.org/resource/Public_company +
|
| http://dbpedia.org/property/wikiPageUsesTemplate
|
http://dbpedia.org/resource/Template:Use_dmy_dates +
, http://dbpedia.org/resource/Template:Use_Australian_English +
, http://dbpedia.org/resource/Template:Asx +
, http://dbpedia.org/resource/Template:Infobox_company +
, http://dbpedia.org/resource/Template:As_of +
, http://dbpedia.org/resource/Template:Reflist +
, http://dbpedia.org/resource/Template:Primary_sources +
, http://dbpedia.org/resource/Template:Main +
, http://dbpedia.org/resource/Template:URL +
|
| http://purl.org/dc/terms/subject
|
http://dbpedia.org/resource/Category:Pharmaceutical_companies_of_Australia +
, http://dbpedia.org/resource/Category:Cancer_organisations_based_in_Australia +
|
| http://www.w3.org/ns/prov#wasDerivedFrom
|
http://en.wikipedia.org/wiki/Immutep?oldid=1085167624&ns=0 +
|
| http://xmlns.com/foaf/0.1/depiction
|
http://commons.wikimedia.org/wiki/Special:FilePath/Logo-immutep-lag-3.svg +
|
| http://xmlns.com/foaf/0.1/isPrimaryTopicOf
|
http://en.wikipedia.org/wiki/Immutep +
|
| http://xmlns.com/foaf/0.1/name
|
Immutep Ltd
|
| owl:sameAs |
http://dbpedia.org/resource/Immutep +
, https://global.dbpedia.org/id/u8n8 +
, http://www.wikidata.org/entity/Q19877253 +
|
| rdf:type |
http://dbpedia.org/ontology/Agent +
, http://www.ontologydesignpatterns.org/ont/dul/DUL.owl#SocialPerson +
, http://www.ontologydesignpatterns.org/ont/dul/DUL.owl#Agent +
, http://schema.org/Organization +
, http://www.wikidata.org/entity/Q4830453 +
, http://www.wikidata.org/entity/Q43229 +
, http://dbpedia.org/ontology/Organisation +
, http://dbpedia.org/ontology/Company +
, http://www.wikidata.org/entity/Q24229398 +
|
| rdfs:comment |
Immutep Ltd (formerly Prima Biomed) is a b … Immutep Ltd (formerly Prima Biomed) is a biotechnology company working primarily in the field of cancer immunotherapy using the LAG3 immune control mechanism. The company was originally built on CVac, a therapeutic cancer vaccine. In late 2014 the privately held French immunotherapy company Immutep SA was purchased by Prima Biotech. Prima currently has three main products in its pipeline, all acquired with Immutep: IMP731, a depleting monoclonal antibody for autoimmune diseases, targeting LAG-3+ activated T cells. This antibody has been licensed to GlaxoSmithKline.body has been licensed to GlaxoSmithKline.
|
| rdfs:label |
Immutep
|
